Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

After coming to the US in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Novo Nordisk was a pioneer in developing GLP-1 ... Skytrofa, a drug for pediatric growth hormone deficiency, won its FDA nod in 2021. That once-weekly injectable medication was developed as ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

On a call with investors last week, Danish drugmaker Novo Nordisk shared some teasers about CagriSema ... and works by ...

The Denmark-based company said it now expects sales growth this year of between 23% and 27% in local currencies, compared to ...